These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1047 related articles for article (PubMed ID: 25670896)

  • 1. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.
    Calverley PM; Eriksson G; Jenkins CR; Anzueto AR; Make BJ; Persson A; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():13-25. PubMed ID: 28031707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials.
    Eriksson G; Calverley PM; Jenkins CR; Anzueto AR; Make BJ; Lindberg M; Fagerås M; Postma DS
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1457-1468. PubMed ID: 28553098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
    Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
    Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluticasone propionate/formoterol for COPD management: a randomized controlled trial.
    Papi A; Dokic D; Tzimas W; Mészáros I; Olech-Cudzik A; Koroknai Z; McAulay K; Mersmann S; Dalvi PS; Overend T
    Int J Chron Obstruct Pulmon Dis; 2017; 12():1961-1971. PubMed ID: 28740376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study.
    Ställberg B; Selroos O; Vogelmeier C; Andersson E; Ekström T; Larsson K
    Respir Res; 2009 Feb; 10(1):11. PubMed ID: 19228428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of budesonide/formoterol and fluticasone/salmeterol combinations in COPD patients: findings from a real-world analysis in an Italian setting.
    Perrone V; Sangiorgi D; Buda S; Degli Esposti L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2749-2755. PubMed ID: 27853362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist.
    Yang HH; Lai CC; Wang YH; Yang WC; Wang CY; Wang HC; Chen L; Yu CJ
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2477-2485. PubMed ID: 28860742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study.
    Larsson K; Janson C; Lisspers K; Jørgensen L; Stratelis G; Telg G; Ställberg B; Johansson G
    J Intern Med; 2013 Jun; 273(6):584-94. PubMed ID: 23495860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of severe exacerbations, poor asthma control, and β-agonist overuse for patients with asthma.
    Patel M; Pilcher J; Reddel HK; Qi V; Mackey B; Tranquilino T; Shaw D; Black P; Weatherall M; Beasley R;
    J Allergy Clin Immunol Pract; 2014; 2(6):751-8. PubMed ID: 25439367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beclomethasone/formoterol in the management of COPD: a randomised controlled trial.
    Calverley PM; Kuna P; Monsó E; Costantini M; Petruzzelli S; Sergio F; Varoli G; Papi A; Brusasco V
    Respir Med; 2010 Dec; 104(12):1858-68. PubMed ID: 20965712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations.
    Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA
    COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Budesonide/formoterol in the treatment of COPD].
    Peces-Barba Romero G; Villar Alvarez F
    Arch Bronconeumol; 2010; 46 Suppl 4():22-7. PubMed ID: 20850023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A US database study characterizing patients initiating a budesonide-formoterol combination versus tiotropium bromide as initial maintenance therapy for chronic obstructive pulmonary disease.
    Kern DM; Williams SA; Tunceli O; Wessman C; Zhou S; Pethick N; Elhefni H; Trudo F
    Int J Chron Obstruct Pulmon Dis; 2014; 9():775-83. PubMed ID: 25071369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.
    Nielsen R; Kankaanranta H; Bjermer L; Lange P; Arnetorp S; Hedegaard M; Stenling A; Mittmann N
    Respir Med; 2013 Nov; 107(11):1709-21. PubMed ID: 23856511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence.
    Blais L; Forget A; Ramachandran S
    Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of salmeterol/fluticasone via single versus separate inhalers on exacerbations in severe/very severe COPD.
    Hagedorn C; Kässner F; Banik N; Ntampakas P; Fielder K
    Respir Med; 2013 Apr; 107(4):542-9. PubMed ID: 23337300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.